Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5NET 2Endocrine 2Dermatologic 1

Conditions

Melanoma 2653Lymphoma, T-Cell, Cutaneous 479Skin Neoplasms 408Carcinoma, Non-Small-Cell Lung 377Mycosis Fungoides 330Neoplasms 319Keratosis, Actinic 300Sezary Syndrome 294Breast Neoplasms 285Neoplasm Metastasis 284Carcinoma, Renal Cell 280Lymphoma, Non-Hodgkin 276Lymphoma 264Carcinoma, Basal Cell 263Lymphoma, Large B-Cell, Diffuse 261Leukemia, Lymphocytic, Chronic, B-Cell 261Lymphoma, Follicular 259Hodgkin Disease 247Lymphoma, Mantle-Cell 245Lymphoma, B-Cell, Marginal Zone 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 243Uveal Melanoma 234Burkitt Lymphoma 233Lymphoma, Large-Cell, Immunoblastic 223Colorectal Neoplasms 196Lymphoma, Large-Cell, Anaplastic 190Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 186Ovarian Neoplasms 181Squamous Cell Carcinoma of Head and Neck 180Lung Neoplasms 179

Interventions

veliparib 1Temozolomide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Non functioning pancreatic endocrine tumor × Dermatologic × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡